Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial
Praveen Kumar Marimuthu, Chitra Renukaradhya, S. Sahu, A. O. John et autres
Background: Non-surgical management of oral cavity squamous cell carcinoma (OSCC) has poorer outcomes compared to surgery. In borderline resectable tumors, historical neoadjuvant chemotherapy achieves surgical conversion in only about 40%. Combining low-dose immunotherapy and oral metronomic therapy (OMT) with chemotherapy may enhance …
in (code pays fourni par la source)
3 citations
The Lancet Regional Health - Southeast Asia